New hope for liver cancer: drug combo targets tumors after immunotherapy fails
NCT ID NCT07238881
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether combining dalpiciclib (a CDK4/6 inhibitor) with camrelizumab (an immunotherapy) can shrink tumors in 30 people with advanced liver cancer that progressed after prior immunotherapy. The study aims to find a new second-line option for this hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dalpiciclib and camrelizumab
- What this could lead to
- If it works, this could offer a new second-line treatment option for people with advanced liver cancer who have already tried immunotherapy.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULCAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.